Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus
Clinical trial NCT05262686 · UNKNOWN
Trial details
- NCT number
- NCT05262686
- Sponsor
- Peking University People's Hospital
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-01
- Primary completion
- 2023-06-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.